What Next for Catalyst Pharmaceuticals, Inc. (CPRX) Stock After Today’s Huge Increase?

April 10, 2018 - By Henry Gaston

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Logo

Investors sentiment decreased to 1.97 in 2017 Q4. Its down 0.03, from 2 in 2017Q3. It turned negative, as 11 investors sold Catalyst Pharmaceuticals, Inc. shares while 19 reduced holdings. 34 funds opened positions while 25 raised stakes. 55.25 million shares or 59.14% more from 34.72 million shares in 2017Q3 were reported.
State Board Of Administration Of Florida Retirement has 20,000 shares for 0% of their portfolio. 3.64M are owned by Vanguard Group Inc Inc. Macquarie Gp has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 2,100 shares. Cwm Limited Company holds 500 shares or 0% of its portfolio. Virtu Lc invested in 0% or 16,764 shares. Geode Capital Mngmt Ltd Limited Liability Company holds 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) or 746,011 shares. D E Shaw Com invested 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Ameritas Invest holds 6,280 shares or 0% of its portfolio. Ghost Tree Ltd Liability Company accumulated 0.5% or 550,000 shares. Moreover, Tanaka has 2.29% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 256,593 shares. Strs Ohio reported 163,000 shares stake. Knott David M accumulated 0.59% or 380,110 shares. Hillsdale Invest Inc owns 17,000 shares. Hightower Lc stated it has 10,411 shares. Stratos Wealth Partners has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 1,500 shares.

Since April 3, 2018, it had 1 buy, and 0 insider sales for $45,800 activity.

The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a huge mover today! The stock increased 9.32% or $0.22 during the last trading session, reaching $2.58. About 564,714 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 24.38% since April 10, 2017 and is uptrending. It has outperformed by 12.83% the S&P500.
The move comes after 8 months positive chart setup for the $264.59M company. It was reported on Apr, 10 by Barchart.com. We have $2.66 PT which if reached, will make NASDAQ:CPRX worth $7.94 million more.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Among 4 analysts covering Catalyst Pharma (NASDAQ:CPRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharma had 6 analyst reports since October 31, 2017 according to SRatingsIntel. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Buy” rating given on Monday, November 27 by SunTrust. The company was maintained on Wednesday, November 1 by Roth Capital. The firm earned “Buy” rating on Thursday, March 15 by H.C. Wainwright. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Buy” rating given on Tuesday, October 31 by SunTrust. The firm earned “Buy” rating on Friday, November 10 by H.C. Wainwright. The stock has “Buy” rating by Piper Jaffray on Friday, December 1.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $264.59 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.